Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Interferon retreatment of chronic hepatitis C may be harmful

People with hepatitis C and chronic liver disease who relapsed or failed to respond to initial treatment are unlikely to improve on interferon retreatment. In fact, they may face an increased risk of dying sooner, and are likely to experience a variety of adverse effects, according to an updated systematic review published in The Cochrane Library.

31 Jan 2013

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Marblar is gamifying the process of technology transfer. We post technology on our platform in the form of a challenge, and the Marblar community then competes to uncover new problems these technologies could solve – thereby discovering new market applications for these technologies.

31 Jan 2013

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMROTM (mipomersen sodium) injection.

30 Jan 2013

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

The U.S. Food and Drug Administration today approved Kynamro (mipomersen sodium) injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH).

30 Jan 2013

Janssen, Medivir and Idenix partner for clinical development of HCV combination therapy

Medivir AB today announced a non-exclusive collaboration between Janssen Pharmaceuticals Inc. (Janssen) and Idenix Pharmaceuticals for the clinical development of an all-oral (interferon-free) direct-acting antiviral (DAA) hepatitis C (HCV) combination therapy.

29 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Undetected comorbidities linked to increased mortality in schizophrenia

Patients with schizophrenia have elevated mortality, the leading causes of which appear to be ischemic heart disease and cancer, a Swedish national cohort study shows.

25 Jan 2013

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease.

23 Jan 2013

SLU team discovers molecular pathway that contributes to triple-negative breast cancer

In research published in the Jan. 17 issue of The Journal of Cell Biology, a team led by Susana Gonzalo, Ph.D., assistant professor of biochemistry and molecular biology at Saint Louis University, has discovered a molecular pathway that contributes to triple-negative breast cancer, an often deadly and treatment resistant form of cancer that tends to strike younger women.

23 Jan 2013

$ADT increases risk of fracture incidence after treatment completion in men with prostate cancer$

ADT increases risk of fracture incidence after treatment completion in men with prostate cancer

In what is believed to be the first study to describe the impact on men with a 'high' risk of bone fracture who are receiving long-term androgen deprivation therapy (ADT) for prostate cancer, new research from The Cancer Institute of New Jersey shows this population to have a higher fracture incidence following treatment completion.

18 Jan 2013

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Today, Boehringer Ingelheim announced that the first patients have been enrolled in the company's pivotal Phase III interferon (IFN)-free hepatitis C (HCV) clinical trial programme, HCVerso.

18 Jan 2013

Octapharma receives FDA approval for Octaplas to treat blood clotting disorders

The U.S. Food and Drug Administration today approved Octaplas, a pooled plasma (human) blood product for the replacement of clotting proteins (coagulation factors) in certain medical conditions where patients have insufficient levels.

18 Jan 2013

SLU researchers examine health outcomes for obese transplant recipients

In a research review article published in the American Journal of Nephrology, Saint Louis University investigators examined data from multiple studies to better understand how obesity, an epidemic in the U.S., impacts kidney transplant patients.

16 Jan 2013

Stroke need not delay bypass surgery

The time since a stroke need not determine when patients undergo elective coronary artery bypass grafting, say researchers.

15 Jan 2013

Greater selectivity in GI bleeding prophylaxis needed

Researchers have developed a risk-scoring system to identify noncritically ill hospital patients most likely to benefit from prophylactic acid-suppressive medication.

14 Jan 2013

Lower liver quality from donation after cardiac death linked to drop in transplants

A new study, funded in part by the National Institutes of Health (NIH) and Health Resources and Services Administration, and published in the January 2013 issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases (AASLD), found that the non-use of donor livers climbed through 2010 due to a worsening of donor liver quality, primarily from donation following cardiac death. Diabetes, donor age, and body mass index (BMI) were also linked to a decrease in use of organs.

11 Jan 2013

Scientists develop playbook to end devastating impact of fibrotic diseases

A team of scientists has developed a playbook for ending the devastating impact of fibrotic diseases of the liver, lung, kidney, and other organs, which are responsible for as many as 45 percent of all deaths in the industrialized world.

11 Jan 2013

SLU researchers to test new screening method for MPS disorders among infants

Researchers at Saint Louis University have received a five-year, $2.5 million National Institutes of Health grant to test a new method of screening newborns for a group of rare, but serious genetic disorders that affect approximately 200 babies born in the U.S., each year.

11 Jan 2013

New scoring system can help clinicians better identify non-ICU patients at risk for GI bleeding

Critically ill patients in hospital intensive care units (ICUs) are routinely prescribed acid-suppressive medications to reduce their risk of developing stress ulcers and gastrointestinal bleeding, both of which can result from being in a stressful environment and from being intubated. Over the years, this routine practice has often been extended to patients outside the ICU, despite a lack of evidence that this population is at significant risk of these complications.

9 Jan 2013

PharmaIN receives FDA orphan-drug designation for terlipressin to treat ascites

PharmaIN Corporation and LAT Pharma LLC today announced that the US Food and Drug Administration (FDA) has granted their request for orphan-drug designation for terlipressin for the treatment of ascites due to all etiologies except for cancer.

7 Jan 2013

Liver Disease News and Research

Further Reading

Interferon retreatment of chronic hepatitis C may be harmful

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

Janssen, Medivir and Idenix partner for clinical development of HCV combination therapy

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Undetected comorbidities linked to increased mortality in schizophrenia

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

SLU team discovers molecular pathway that contributes to triple-negative breast cancer

ADT increases risk of fracture incidence after treatment completion in men with prostate cancer

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Octapharma receives FDA approval for Octaplas to treat blood clotting disorders

SLU researchers examine health outcomes for obese transplant recipients

Stroke need not delay bypass surgery

Greater selectivity in GI bleeding prophylaxis needed

Lower liver quality from donation after cardiac death linked to drop in transplants

Scientists develop playbook to end devastating impact of fibrotic diseases

SLU researchers to test new screening method for MPS disorders among infants

New scoring system can help clinicians better identify non-ICU patients at risk for GI bleeding

PharmaIN receives FDA orphan-drug designation for terlipressin to treat ascites

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News